Pfizer Limited reported its audited financial results for the year ended March 31, 2026, approved by the Board of Directors on May 12, 2026. The company posted revenue from operations of ₹2,519.65 crore for the full year, up from ₹2,281.35 crore in the previous year. Total income, including other income of ₹187.95 crore, stood at ₹2,707.60 crore compared to ₹2,453.60 crore in the prior year. The financial results were audited by statutory auditors M/s. B S R & Co. LLP, whose report carries an unmodified opinion.

Financial Performance

The company's profit before tax and exceptional items improved to ₹1,024.83 crore from ₹843.28 crore in the previous year. After accounting for exceptional items of ₹(49.16) crore — primarily comprising personnel separation costs and provisions related to New Labour Codes — profit before tax stood at ₹975.67 crore against ₹1,016.09 crore previously. Net profit for the year came in at ₹722.43 crore compared to ₹767.60 crore in the prior year. Total comprehensive income for the year was ₹726.27 crore versus ₹768.34 crore previously.

The following table summarises the key financial metrics for the year:

Quarterly Performance

For the quarter ended March 31, 2026, Pfizer reported revenue from operations of ₹629.23 crore and total income of ₹669.95 crore. Net profit for the quarter stood at ₹199.82 crore. Basic and diluted earnings per share for the quarter were ₹43.68, while EPS before exceptional items was ₹42.21.

Balance Sheet Highlights

As at March 31, 2026, Pfizer's total assets stood at ₹4,921.88 crore compared to ₹4,911.11 crore as at March 31, 2025. Total equity was ₹4,202.90 crore, comprising equity share capital of ₹45.75 crore and other equity of ₹4,157.15 crore. Cash and cash equivalents at the end of the year were ₹102.66 crore, down from ₹495.07 crore at the start of the year, reflecting significant dividend payouts and fixed deposit placements during the period.

Cash Flow Summary

Net cash generated from operating activities for the year was ₹967.57 crore, compared to ₹659.75 crore in the previous year. Net cash used in investing activities was ₹(561.67) crore, largely on account of fixed deposits placed (net) of ₹(714.59) crore, partially offset by interest received of ₹176.99 crore. Net cash used in financing activities was ₹(798.31) crore, which included dividend paid of ₹(751.64) crore.

Dividend and AGM Details

The Board of Directors recommended a final dividend of Rs 75 per equity share of Rs 10 each (750%) for the financial year ended March 31, 2026. The proposed dividend amounts to ₹343.11 crore and is subject to shareholder approval at the ensuing Annual General Meeting. The record date for determining shareholder eligibility has been fixed as Friday, July 17, 2026, and the dividend is scheduled to be paid on or after August 4, 2026. The 75th Annual General Meeting of the Company is convened for Tuesday, July 28, 2026, to be held through Video-Conferencing / Other Audio-Visual Means.

Exceptional Items and Other Developments

Exceptional items for the year ended March 31, 2026 amounted to a net charge of ₹49.16 crore. This includes a charge of ₹41.73 crore towards personnel separation costs for field force and marketing teams arising from an exclusive Supply and Marketing Agreement with Cipla Limited for four brands — Corex Dx, Corex LS, Dolonex, and Neksium — as well as separation costs for other support functions. Additionally, a provision of ₹7.43 crore was recognised following an assessment of the impact of the New Labour Codes, which came into effect on November 21, 2025. In the previous year, exceptional items included a net gain of ₹172.81 crore from the assignment of MIDC Land lease and sale of the building thereon.

The Board also appointed M/s. Kishore Bhatia & Associates (Firm Registration No. 000294) as Cost Auditors for the financial year ending March 31, 2027, subject to shareholder ratification at the AGM. The company confirmed it operates solely in the Pharmaceuticals segment and does not qualify as a Large Corporate as at March 31, 2026, having no outstanding debt securities, long-term borrowings exceeding Rs 1,000 crore, or credit ratings relating to borrowings.

Source: None/Company/INE182A01018/59ff6727e1374061.pdf

Pfizer Limited has announced the scheduling of its 75th Annual General Meeting (AGM), with the Board of Directors approving the date at their meeting held on May 12, 2026. The intimation was filed with BSE Limited and the National Stock Exchange of India Ltd. pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

AGM Details

The 75th AGM is set to be held on Tuesday, July 28, 2026, and will be conducted through Video-Conferencing (VC) or Other Audio-Visual Means (OAVM). The virtual format is in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

The key details of the upcoming AGM are summarised below:

Regulatory Compliance

The intimation was submitted to both BSE Limited and the National Stock Exchange of India Ltd. in line with the company's disclosure obligations. The filing was signed by Prajeet Nair, Director – Corporate Services & Company Secretary, on May 12, 2026.